New generation of medications according to study in some respects better than warfarin millions of Marcumar users in Germany are waiting excitedly for early 2011: then come a drug for patients with heart atrial fibrillation on the market, which should be better and above all even than the hitherto commonly prescribed Blutgerinnungshemmer Marcumar. The RELY study says that the Dabigatran at least equivalent and in some respects is superior to even the Marcumar. Gone are thus the annoying checks by quick – or INR value & co. and the laborious dosage? In Germany’s first extensive interview on the subject of Cologne chief physician and cardiologist Prof. Dr. Marc Horlitz answered (hospital Porz am Rhein;) essential questions about the effect of the new generation of Blutgerinnungshemmern. Some voices already speak of a paradigm shift in the treatment and there is also evidence that justify this assessment,”so, Horlitz Prof.
in the interview, the in the Online health magazine is published. Dabigatran is given in the study of RELY-in two different doses, 110 mg and 150 mg once, once. Both doses had significant advantages over the Marcumar “, says Prof. Horlitz. Read what advantages are and how they specifically affect why Prof.
Horlitz warns of yet anyway, too much euphoria. A free and independent online health magazine for the Rheinland and Ruhr area and is published by a group of freelance journalist from the region. rheinruhrmed.de is a pure information portal (without any consulting activity!); the online magazine is financed exclusively through advertising. M. Rabe.